CN1111739C - Blood coagulation, fibrinolytic function dynamic measurement reagent - Google Patents
Blood coagulation, fibrinolytic function dynamic measurement reagent Download PDFInfo
- Publication number
- CN1111739C CN1111739C CN97100956A CN97100956A CN1111739C CN 1111739 C CN1111739 C CN 1111739C CN 97100956 A CN97100956 A CN 97100956A CN 97100956 A CN97100956 A CN 97100956A CN 1111739 C CN1111739 C CN 1111739C
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- blood
- distilled water
- milliliter
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a kind of dynamic test agent of blood coagulation, fibrinolytic function of testing blood, belong to the analysis of material technical field used the chemical detection of blood.It consists of (every milliliter of blood plasma): urokinase 50-2000 unit, sodium chloride 0.7-7.0 milligram, lime chloride 0.2-5 milligram, sodium acetate 0.5-10 milligram, barbital sodium 3-25 milligram, hydrochloric acid 0.02-0.3 milliequivalent, distilled water 600-6000 microlitre.The present invention can detect the full dynamic process of blood clotting to fibrinolytic simultaneously, reacts two system dynamics equilibrium states.
Description
Technical field
The invention belongs to the analysis of material technical field used (classification number is GO1N33/48), be specifically related to a kind of blood coagulation, fibrinolytic function dynamic measurement reagent of testing blood the chemical detection of blood.
Technical background
Normal condition servant's blood is liquid, solid son of multiple blood coagulation and anticoagulin are arranged in the blood, coagulant and anticoagulant substances, the solid son and the material of these mutual antagonisms are in relative equilibrium, be that blood clotting and fibrinolytic are in dynamic balance state to keep the liquid state of blood, guarantee the transmission of each tissue of human body and each organ metabolism material.Blood clotting and fibrinolytic are to be transformed and the complicated reacting condition process of the enzyme institute catalysis that forms by a series of proenzymes, if clotting factor is activated, it is hyperfunction to produce coagulation function, even hypercoagulative state occurs, initiation cerebral thrombus.Coronary artery thrombosises etc. then hypocoagulability may occur on the contrary, take place subcutaneous.Mucous membrane.Intestines and stomach and wound bleeding.Therefore, to blood coagulation.The fibrinolytic system determination of activity is paid close attention to by clinical medicine always, but what medically taked at present all is unilaterally to use coagulant.Or cellosolve tests the state of blood clotting or fibrinolytic respectively, and these reagent can't detect two system activities height and detect two systems whether be in dynamic balance state simultaneously.
Summary of the invention
The objective of the invention is to deficiency, provide a kind of and can detect full dynamic process from blood clotting to the fibrinolysis simultaneously, thereby detect the blood coagulation of two system dynamics equilibrium states at the prior art existence.Fibrinolytic function detection of dynamic reagent.
This detectable is made up of following composition:
[UK] urokinase 50-2000 unit (u)/milliliter blood plasma.(NaCl) sodium chloride 0.7-7 mg/ml blood plasma.(CaCl
2) lime chloride 0.2-5 mg/ml blood plasma.Sodium acetate 0.5-10 mg/ml blood plasma.Barbital sodium 3-25 mg/ml blood plasma.(HCl) hydrochloric acid 0.02-0.3 milliequivalent/milliliter blood plasma.(DH
2O) distilled water 600-6000 microlitre/milliliter blood plasma.
Deposit for convenience, this detectable is divided into three groups of A.B.C, then mixes during use simultaneously to add:
The A group: urokinase 50-2000 units per ml blood plasma, sodium chloride 0.2-2.0 mg/ml are cellosolve to slurry, distilled water 50-500 microlitre/milliliter blood plasma.
The B group: lime chloride 0.2-5 mg/ml blood plasma, distilled water 50-500 microlitre/milliliter blood plasma are coagulant.
The C group: sodium acetate 0.5-10 mg/ml blood plasma, barbital sodium 3-25 mg/ml blood plasma, sodium chloride 0.5-5.0 mg/ml blood plasma, hydrochloric acid 0.02-0.3 milliequivalent/milliliter blood plasma, distilled water 500-5000 microlitre/milliliter blood plasma are plasma extender.
The content preferable range of this detectable composition is:
A group: by urokinase 300-700 unit (u)/milliliter blood plasma, sodium chloride 0.62-1.1 mg/ml blood plasma, distilled water 90-150 microlitre/milliliter blood plasma.
B group: by lime chloride 2.85-3.901 mg/ml blood plasma, distilled water 105-200 microlitre/milliliter blood plasma.
C group: by sodium acetate 3.21-6.45 mg/ml blood plasma, barbital sodium 9.25-19.1 mg/ml blood plasma, sodium chloride 0.93-3.1 mg/ml blood plasma, hydrochloric acid 0.02-0.21 milliequivalent (MN)/milliliter blood plasma, distilled water 1240-3540 microlitre/milliliter blood plasma.
This blood coagulation, the mechanism of fibrinolytic function dynamic measurement reagent is: after detected blood plasma is added this test agent in proportion, clotting factor in coagulant and the blood plasma reacts, make its clotting factor activation, through after a series of enzymatic reactions, liquid fibrinogen changes the fibrin of gel state into; Owing to the activation of cellosolve to plasminogen in the blood plasma, plasminogen changes fibrinoclase into, makes the fibrinolysis of gel state become liquid state again simultaneously.Like this, blood plasma begins to react the total overall reaction of end just by objective to fibrinolytic from hemagglutination.Comprehensively.Dynamically reflected.
Compound method of the present invention is conventional preparation, by the amount of tested blood plasma, once adds this reagent in proportion and gets final product during use, and testing result is drawn by the molten dynamic figure instrument of blood coagulation one fibrinolytic of inventor's invention.
The present invention is the blood coagulation of human body simultaneously.Fibrinolytic two system activities height detects two system dynamics equilibrium states.Help the doctor in view of the above patient's the state of an illness to be made accurate diagnosis.
Embodiment
Every milliliter of blood plasma of embodiment 1:()
A group: urokinase 220 units (u).0.4 milligram in sodium chloride.Distilled water 80 microlitres.
B group: 0.26 milligram in lime chloride.Distilled water 100 microlitres.
C group: 0.26 milligram of sodium acetate.5.37 milligrams of barbital sodiums.0.89 milligram in sodium chloride.Hydrochloric acid 0.12 milliequivalent.Distilled water 620 microlitres.
Every milliliter of blood plasma of embodiment 2:()
A group: urokinase 900 units (u).1.1 milligrams in sodium chloride.Distilled water 200 microlitres.
B group: 2.25 milligrams in lime chloride.Distilled water 285 microlitres.
C group: 6.12 milligrams of sodium acetates.11.26 milligrams of barbital sodiums.2.42 milligrams in sodium chloride.Hydrochloric acid 0.25 milliequivalent.Distilled water 2600 microlitres.
Every milliliter of blood plasma of embodiment 3:()
A group: urokinase 1600 units (u).1.7 milligrams in sodium chloride.Distilled water 400 microlitres.
B group: 4.67 milligrams in lime chloride.Distilled water 420 microlitres.
C group: 8.47 milligrams of sodium acetates.21.23 milligrams of barbital sodiums.4.10 milligrams in sodium chloride.Hydrochloric acid 0.27 milliequivalent.Distilled water 4200 microlitres.
Every milliliter of blood plasma of embodiment 4:()
A group: urokinase 50 units (u).0.2 milligram in sodium chloride.Distilled water 50 microlitres.
B group: 0.2 milligram in lime chloride.Distilled water 50 microlitres.
C group: 0.5 milligram of sodium acetate.3 milligrams of barbital sodiums.0.5 milligram in sodium chloride.Hydrochloric acid 0.02 milliequivalent.Distilled water 500 microlitres.
Every milliliter of blood plasma of embodiment 5:()
A group: urokinase 2000 units (u).2.0 milligrams in sodium chloride.Distilled water 500 microlitres.
B group: 5 milligrams in lime chloride.Distilled water 500 microlitres.
C group: 10 milligrams of sodium acetates.25 milligrams of barbital sodiums.5 milligrams in sodium chloride.Hydrochloric acid 0.3 milliequivalent.Distilled water 5000 microlitres.
Every milliliter of blood plasma of embodiment 6:()
A group: urokinase 300 units (u).0.62 milligram in sodium chloride.Distilled water 90 microlitres.
B group: 2.85 milligrams in lime chloride.Distilled water 105 microlitres.
C group: 3.21 milligrams of sodium acetates.9.25 milligrams of barbital sodiums.0.93 milligram in sodium chloride.Hydrochloric acid 0.02 milliequivalent.Distilled water 1240 microlitres.
Every milliliter of blood plasma of embodiment 7:()
A group: urokinase 700 units (u).1.1 milligrams in sodium chloride.Distilled water 150 microlitres.
B group: 3.901 milligrams in lime chloride.Distilled water 200 microlitres.
C group: 6.45 milligrams of sodium acetates.19.1 milligrams of barbital sodiums.3.1 milligrams in sodium chloride.Hydrochloric acid 0.21 milliequivalent.Distilled water 3540 microlitres.
Claims (3)
1, a kind of blood coagulation, fibrinolytic function dynamic measurement reagent, its feature is made up of urokinase 50-2000 units per ml blood plasma, sodium chloride 0.7-7.0 mg/ml blood plasma, lime chloride 0.2-5 mg/ml blood plasma, sodium acetate 0.5-10 mg/ml blood plasma, barbital sodium 3-25 mg/ml blood plasma, hydrochloric acid 0.02-0.3 milliequivalent/milliliter blood plasma, distilled water 600-6000 microlitre/milliliter blood plasma at it.
2, blood coagulation according to claim 1, fibrinolytic function dynamic measurement reagent is characterized in that it is divided into three groups of A, B, C:
The A group is made up of urokinase 50-2000 units per ml blood plasma, sodium chloride 0.2-2.0 mg/ml blood plasma, distilled water 50-500 microlitre/milliliter blood plasma.
The B group is made up of lime chloride 0.2-5 mg/ml blood plasma, distilled water 50-500 microlitre/milliliter blood plasma.
The C group is made up of sodium acetate 0.5-10 mg/ml blood plasma, barbital sodium 3-25 mg/ml blood plasma, sodium chloride 0.5-5 mg/ml blood plasma, hydrochloric acid 0.02-0.3 milliequivalent/milliliter blood plasma, distilled water 500-5000 microlitre/milliliter blood plasma.
3, blood coagulation according to claim 2, fibrinolytic function dynamic measurement reagent is characterized in that A, B, three groups of content of C are:
The A group is made up of urokinase 300-700 units per ml blood plasma, sodium chloride 0.62-1.1 mg/ml blood plasma, distilled water 90-150 microlitre/milliliter blood plasma;
The B group is made up of lime chloride 2.85-3.901 mg/ml blood plasma, distilled water 105-200 microlitre/milliliter blood plasma;
The C group is made up of sodium acetate 3.21-6.45 mg/ml blood plasma, barbital sodium 9.25-19.1 mg/ml blood plasma, sodium chloride 0.93-3.1 mg/ml blood plasma, hydrochloric acid 0.02-0.21 milliequivalent/milliliter blood plasma, distilled water 1240-3540 microlitre/milliliter blood plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97100956A CN1111739C (en) | 1997-02-04 | 1997-02-04 | Blood coagulation, fibrinolytic function dynamic measurement reagent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97100956A CN1111739C (en) | 1997-02-04 | 1997-02-04 | Blood coagulation, fibrinolytic function dynamic measurement reagent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1190187A CN1190187A (en) | 1998-08-12 |
| CN1111739C true CN1111739C (en) | 2003-06-18 |
Family
ID=5165430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97100956A Expired - Fee Related CN1111739C (en) | 1997-02-04 | 1997-02-04 | Blood coagulation, fibrinolytic function dynamic measurement reagent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111739C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10145626B2 (en) | 2013-11-15 | 2018-12-04 | General Electric Technology Gmbh | Internally stiffened extended service heat recovery steam generator apparatus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063425A (en) * | 1965-01-04 | 1967-03-30 | Grace W R & Co | Process for the polymerisation of styrene |
| US4216291A (en) * | 1975-09-19 | 1980-08-05 | Leuven Research & Development V.Z.W. | Thrombosis-test |
| CN1102438A (en) * | 1993-07-15 | 1995-05-10 | 格吕伦塔尔有限公司 | Bifunctional variants of urokinase with improved fibrinolytic properties and thrombin-inhibiting activity |
| US5468505A (en) * | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
-
1997
- 1997-02-04 CN CN97100956A patent/CN1111739C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063425A (en) * | 1965-01-04 | 1967-03-30 | Grace W R & Co | Process for the polymerisation of styrene |
| US4216291A (en) * | 1975-09-19 | 1980-08-05 | Leuven Research & Development V.Z.W. | Thrombosis-test |
| US5468505A (en) * | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
| CN1102438A (en) * | 1993-07-15 | 1995-05-10 | 格吕伦塔尔有限公司 | Bifunctional variants of urokinase with improved fibrinolytic properties and thrombin-inhibiting activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1190187A (en) | 1998-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grip | Inflammatory bowel disease promotes venous thrombosis earlier in life | |
| Marder et al. | Detection of serum fibrinogen and fibrin degradation products: Comparison of six technics using purified products and application in clinical studies | |
| US7595169B2 (en) | Method for determining percent platelet aggregation | |
| Jörneskog et al. | Altered properties of the fibrin gel structure in patients with IDDM | |
| CA2032561C (en) | Method of determining levels of extrinsic and intrinsic clotting factors and protein c | |
| Kario et al. | Which factors affect high D-dimer levels in the elderly? | |
| CN108982865A (en) | A kind of thrombelastogram method heparin immue quantitative detection reagent box and preparation method thereof | |
| Gurewich et al. | A comparative study of precipitation and paracoagulation by protamine sulfate and ethanol gelation tests | |
| CN1111739C (en) | Blood coagulation, fibrinolytic function dynamic measurement reagent | |
| CA2555979A1 (en) | Factor xa-based heparin assay using a heparin-modifying component | |
| JP5212821B2 (en) | Enzyme assay using a modified substrate containing a substrate that binds to a polymer via a spacer | |
| Bounameaux et al. | Laboratory diagnosis of pulmonary embolism: value of increased levels of plasma D-dimer and thrombin—antithrombin III complexes | |
| CN108624680B (en) | The application of RAE1 gene or albumen as the biomarker of diagnosing myocardial infarction | |
| Nagamatsu et al. | Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate | |
| CN108796067B (en) | The diagnosis new function of MAEA gene in blood | |
| Retzinger et al. | Complexation with heparin prevents adhesion between fibrin-coated surfaces. | |
| US4960694A (en) | Test combination and method of detecting fibrin monomers in blood | |
| Yun et al. | Electrochemical sensors for polyionic macromolecules: development and applications in pharmaceutical research | |
| CN108753956A (en) | Application of the KDSR genes in preparing myocardial infarction diagnosis tool | |
| Joy et al. | Effect of p H on the stability of heparin in 5% dextrose solutions | |
| Lynch et al. | Preoperative AT-III values and clinical postoperative thrombosis: a comparison of three antithrombin-III assays | |
| Guo et al. | Homogeneous enzyme-based binding assay for studying glycosaminoglycan interactions with macromolecules and peptides | |
| CN108796068A (en) | DOCK10 genes for early diagnosing myocardial infarction | |
| Carr Jr et al. | Detection of an abnormal plasma clot structure by a simple rigidity assay | |
| AU5681999A (en) | Receptor for underivatized, aqueous soluble beta-(1,3)-glucan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |